文章：

靶向YY1在胶质母细胞瘤中的治疗意义

Therapeutic Implications of Targeting YY1 in Glioblastoma

原文发布日期：30 May 2024

DOI: 10.3390/cancers16112074

类型: Article

开放获取: 是

英文摘要：

The transcription factor Yin Yang 1 (YY1) plays a pivotal role in the pathogenesis of glioblastoma multiforme (GBM), an aggressive form of brain tumor. This review systematically explores the diverse roles of YY1 overexpression and activities in GBM, including its impact on the tumor microenvironment (TME) and immune evasion mechanisms. Due to the poor response of GBM to current therapies, various findings of YY1-associated pathways in the literature provide valuable insights into novel potential targeted therapeutic strategies. Moreover, YY1 acts as a significant regulator of immune checkpoint molecules and, thus, is a candidate therapeutic target in combination with immune checkpoint inhibitors. Different therapeutic implications targeting YY1 in GBM and its inherent associated challenges encompass the use of nanoparticles, YY1 inhibitors, targeted gene therapy, and exosome-based delivery systems. Despite the inherent complexities of such methods, the successful targeting of YY1 emerges as a promising avenue for reshaping GBM treatment strategies, presenting opportunities for innovative therapeutic approaches and enhanced patient outcomes.

摘要翻译： 

转录因子阴阳1（YY1）在多形性胶质母细胞瘤（GBM）这一侵袭性脑肿瘤的发病机制中起着关键作用。本综述系统探讨了YY1在GBM中的过表达及其活性的多重作用，包括其对肿瘤微环境（TME）和免疫逃逸机制的影响。鉴于GBM对现有疗法反应不佳，文献中关于YY1相关通路的多种发现为新型潜在靶向治疗策略提供了宝贵见解。此外，YY1作为免疫检查点分子的重要调节因子，成为与免疫检查点抑制剂联合治疗的候选靶点。针对GBM中YY1的不同治疗策略及其固有挑战包括纳米颗粒、YY1抑制剂、靶向基因疗法以及基于外泌体的递送系统的应用。尽管这些方法本身具有复杂性，但成功靶向YY1已成为重塑GBM治疗策略的重要方向，为创新治疗方法和改善患者预后提供了新的机遇。

原文链接：

Therapeutic Implications of Targeting YY1 in Glioblastoma